Seeking Alpha

The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE...

The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE alongside gemcitabine for patients with advanced pancreatic cancer. (PR)
Comments (1)
  • Chris DeMuth Jr.
    , contributor
    Comments (4346) | Send Message
     
    Investors interested in this drug should consider spending some time studying the CELGZ CVR.
    23 May 2013, 08:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector